PTC cuts 25% of its work­force to save mon­ey amid big com­pa­ny re­vamp 

Rare dis­ease com­pa­ny PTC Ther­a­peu­tics is lay­ing off an ad­di­tion­al 25% of its work­force as it dis­con­tin­ues gene ther­a­py ef­forts and works on sal­vaging its Duchenne mus­cu­lar dy­s­tro­phy drug Translar­na in Eu­rope.

The ma­jor­i­ty of af­fect­ed em­ploy­ees work in ear­ly-stage re­search and PTC’s gene ther­a­py man­u­fac­tur­ing fa­cil­i­ty lo­cat­ed in Hopewell, NJ. Em­ploy­ees work­ing in sales and gen­er­al and ad­min­is­tra­tive func­tions are al­so af­fect­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.